Effectiveness of the Bedaquiline, Pretomanid, and Linezolid Regimen, With or Without Moxifloxacin, for Drug-Resistant Tuberculosis in Ukraine Under Programmatic Conditions.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 40280886.
- Also identified by DOI 10.1093/cid/ciaf214 and PMC identifier 12596402.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Bedaquiline, pretomanid, and linezolid, with or without moxifloxacin, have revolutionized treatment for drug-resistant tuberculosis. In Ukraine, we observed an 86% success rate (394 of 460) under programmatic conditions when drugs were accessible, exceeding prior estimates (58%) and aligning with trial findings (80%-90%). However, access and implementation remain a concern in conflict-affected settings.
Medical subject headings
- Linezolid
- Moxifloxacin
- Diarylquinolines
- Tuberculosis, Multidrug-Resistant
- Antitubercular Agents
- Nitroimidazoles